US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altech Digitial Co.

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:- -

Open:- -

Low:- -

Close:- -

52wk High:- -

52wk Low:- -

Shares:29.50M

Float Shares:1.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:259.58%

ROA:48.64%

PB:0.00

PE(LYR):- -

Loading ...

Overview Company News Filings

Ampol (ASX:ALD) Takes On Some Risk With Its Use Of Debt

Simply Wall St.

1 Super Semiconductor Stock (Besides Nvidia or Broadcom) to Buy Hand Over Fist

Press Release: Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Altimmune to Participate in Two Upcoming Investor Conferences

Guinea's Nimba Mining SA Bauxite Mine Set for Production Restart?

Ampol Limited's (ASX:ALD) top owners are retail investors with 50% stake, while 50% is held by institutions

Simply Wall St.

Press Release: Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Hong Kong IT Services Company Altech Digital (ALD.US) Files for US IPO, Seeks to Raise $6 Million

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Beyond Lithography Machines: Why Photomasks Are the Real Game-Changer

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Adisyn Confirms Delivery of Deposition System; Shares Rise 7%

MT Newswires Live

Press Release: GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

Press Release: Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","market":"US","secType":"STK","nameCN":"Altech Digitial Co.","latestPrice":0,"timestamp":1760731200000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":1500000,"shares":29500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"10-17 16:00:00 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1760500800000,"exchange":"NASDAQ","adjPreClose":0,"sharesOutstanding":400000,"nav":44.492139,"aum":17756473.36,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","floatShares":1500000,"roa":"48.64%","roe":"259.58%","lyrEps":0,"shares":29500000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575976839","title":"Ampol (ASX:ALD) Takes On Some Risk With Its Use Of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2575976839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575976839?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:00","pubTimestamp":1760558404,"startTime":"0","endTime":"0","summary":"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-asxald-takes-on-some-risk-with-its-use-of-debt-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-asxald-takes-on-some-risk-with-its-use-of-debt-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7065","EBIT","ALD.AU","ALD"],"gpt_icon":0},{"id":"2572532164","title":"1 Super Semiconductor Stock (Besides Nvidia or Broadcom) to Buy Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2572532164","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572532164?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:45","pubTimestamp":1759326300,"startTime":"0","endTime":"0","summary":"Investors should start looking beyond prominent names in the AI infrastructure space.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835396%2Fanalyst_analyzing_stock_charts_on_desktop_and_laptop.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835396%2Fanalyst_analyzing_stock_charts_on_desktop_and_laptop.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/01/1-semiconductor-stock-besides-nvidia-or-broadcom/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/01/1-semiconductor-stock-besides-nvidia-or-broadcom/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1066051498.USD","IE00BQXX3F31.USD","SNVD.UK","NVD","NVDD","LU2290526834.HKD","2NVD.UK","LRCX","LU1852331112.SGD","NVD3.UK","3NVD.UK","AVGOP","HK0000306685.HKD","SAM","LU0276348264.USD","LU1037948897.HKD","LU2063271972.USD","NVIW.SI","NVDX","LU2108987350.USD","LU1242518931.SGD","LU1861127337.USD","LU1935043536.SGD","IE00BQXX3C00.GBP","NVD2.UK","SOXX","LU0265550359.USD","LU0345768153.USD","NVDS.UK","LU1989772923.USD","GAA","LU0557290698.USD","NVDU","NVDS","NVDY","ALD","SMH","LU1923622291.USD","LU2244417387.USD","LU0127658192.USD","LU2433249047.HKD","LU2213496289.HKD","LU1989772840.SGD","LU1815336760.USD"],"gpt_icon":1},{"id":"2571380575","title":"Press Release: Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide","url":"https://stock-news.laohu8.com/highlight/detail?id=2571380575","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571380575?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:30","pubTimestamp":1759145400,"startTime":"0","endTime":"0","summary":"Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH. Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises. \"We are thrilled to welcome Christophe to the team at this crucial juncture in Altimmune's evolution,\" said Vipin K. Garg, Ph.D., President and CEO of Altimmune. \"He brings a wealth of experience across mid- and late-stage clinical development, regulatory approvals and commercial launches that will be invaluable as we continue to advance pemvidutide and work toward our mission of establishing a new standard of care in the treatment of hepato-metabolic disorders. On behalf of the executive team and Board of Directors, I would also like to thank Scott for his instrumental contributions over the last six years. His oversight of the pemvidutide program through multiple INDs and clinical trials has positioned us well as we prepare to enter Phase 3 development in MASH.\". Dr. Arbet-Enge","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4232","BK4139","LU1878469433.USD","BK4599","BK4022","R","ALD"],"gpt_icon":0},{"id":"2569797843","title":"Altimmune to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2569797843","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569797843?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:30","pubTimestamp":1758627000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Sept.  23, 2025  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/23/3154577/0/en/Altimmune-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"1174590295","title":"Guinea's Nimba Mining SA Bauxite Mine Set for Production Restart?","url":"https://stock-news.laohu8.com/highlight/detail?id=1174590295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174590295?lang=en_us&edition=fundamental","pubTime":"2025-09-17 10:51","pubTimestamp":1758077471,"startTime":"0","endTime":"0","summary":"Expectations for the resumption of production at Guinea's newly established Nimba Mining SA continue to strengthen. The company was reorganized based on the former Guinea Alumina Corporation (GAC)...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD","SINA"],"gpt_icon":0},{"id":"2567121415","title":"Ampol Limited's (ASX:ALD) top owners are retail investors with 50% stake, while 50% is held by institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2567121415","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567121415?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:40","pubTimestamp":1757968841,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Ampol by retail investors implies that the general public has more power to...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-limiteds-asxald-top-owners-are-retail-investors-with-5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-limiteds-asxald-top-owners-are-retail-investors-with-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD","BK7065","ALD.AU"],"gpt_icon":0},{"id":"2567169121","title":"Press Release: Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2567169121","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567169121?lang=en_us&edition=fundamental","pubTime":"2025-09-15 19:30","pubTimestamp":1757935800,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Sept. 15, 2025  -- Altimmune, Inc. , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises and contributed to a variety of business development transactions.In connection with being named as Chief Commercial Officer, Ms. Richardson will receive, in the aggregate, options to purchase 278,000 shares of Altimmune's common stock, and 96,000 restricted stock units . The options will have an exercise price equal to the clos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4599","BK4232","LU1878469433.USD","ALD","BK4022","R","BK4139"],"gpt_icon":0},{"id":"1141642263","title":"Hong Kong IT Services Company Altech Digital (ALD.US) Files for US IPO, Seeks to Raise $6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1141642263","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141642263?lang=en_us&edition=fundamental","pubTime":"2025-08-22 14:32","pubTimestamp":1755844359,"startTime":"0","endTime":"0","summary":"Hong Kong-based IT system development, maintenance and consulting services provider Altech Digital filed an initial public offering (IPO) application with the U.S. Securities and Exchange Commission...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2560195003","title":"Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2560195003","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560195003?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:30","pubTimestamp":1755603000,"startTime":"0","endTime":"0","summary":"Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug.  19, 2025  (GLOBE NEWSWIRE) ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/19/3135602/0/en/Altimmune-Announces-FDA-Fast-Track-Designation-for-Pemvidutide-in-Alcohol-Use-Disorder-AUD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQQ9H92.USD","BK4585","BK4567","BK4104","FAST","IE00B5TLWC47.USD","IE00BFXG0V08.USD","BK4588","ALD"],"gpt_icon":0},{"id":"1172441429","title":"Beyond Lithography Machines: Why Photomasks Are the Real Game-Changer","url":"https://stock-news.laohu8.com/highlight/detail?id=1172441429","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172441429?lang=en_us&edition=fundamental","pubTime":"2025-08-18 18:23","pubTimestamp":1755512613,"startTime":"0","endTime":"0","summary":"When billions of transistors are packed into a chip no larger than a fingernail, few people ask: how were these circuit patterns, smaller than bacteria, originally \"drawn\"? The answer lies behind a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOK","ALD"],"gpt_icon":0},{"id":"2558571396","title":"Altimmune Board of Directors Appoints Jerry Durso as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2558571396","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558571396?lang=en_us&edition=fundamental","pubTime":"2025-08-11 19:30","pubTimestamp":1754911800,"startTime":"0","endTime":"0","summary":"Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Dire","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130805/0/en/Altimmune-Board-of-Directors-Appoints-Jerry-Durso-as-Chairman.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2557391255","title":"Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2557391255","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557391255?lang=en_us&edition=fundamental","pubTime":"2025-08-05 19:30","pubTimestamp":1754393400,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Aug.  05, 2025  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/05/3127231/0/en/Altimmune-to-Report-Second-Quarter-2025-Financial-Results-and-Provide-Business-Update-on-August-12-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2550341326","title":"Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550341326","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550341326?lang=en_us&edition=fundamental","pubTime":"2025-07-09 19:30","pubTimestamp":1752060600,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., July  09, 2025  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiome","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112467/0/en/Altimmune-Announces-Initiation-of-RESTORE-Phase-2-Trial-Evaluating-the-Efficacy-and-Safety-of-Pemvidutide-in-Alcohol-Associated-Liver-Disease-ALD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0053671581.USD","LU0979878070.USD","BK4588","ELF","LU1242518931.SGD","BK4585","LU1242518857.USD","ALD","BK4183","LU0566484027.USD"],"gpt_icon":0},{"id":"2542363508","title":"Adisyn Confirms Delivery of Deposition System; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542363508","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542363508?lang=en_us&edition=fundamental","pubTime":"2025-06-10 11:15","pubTimestamp":1749525314,"startTime":"0","endTime":"0","summary":"Adisyn  confirmed the delivery of an atomic layer deposition  system to its subsidiary, 2D Generation, as part of plans to commercialize its low-temperature ALD graphene technology, according to a Tuesday filing with the Australian bourse.The company paid Beneq, the manufacturer, AU$600,000 upon delivery, with AU$150,000 payable upon commissioning of the system, the filing said.The system will undergo installation and commissioning, including calibration, test cycles, and integration into the upgraded infrastructure, per the filing.Shares rose 7% in midday trade on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7065","ALD","ALD.AU","AI1.AU","BK7043"],"gpt_icon":0},{"id":"2535174960","title":"Press Release: GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535174960","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535174960?lang=en_us&edition=fundamental","pubTime":"2025-05-14 17:28","pubTimestamp":1747214880,"startTime":"0","endTime":"0","summary":"GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease . -- Affecting up to 5% of the global population, SLD represents an area of. significant unmet medical need with limited treatment options. -- Phase II data show potential of efimosfermin to reverse liver fibrosis,-- Unique properties offer potential for efimosfermin to be a new. -- Significantly expands GSK's hepatology pipeline aimed at addressing. steatotic and viral drivers of liver disease, offering multiple. development options and potential first launch in 2029. GSK plc  and Boston Pharmaceuticals, a leading clinical. entered into an agreement under which GSK will acquire Boston. to treat and prevent progression of steatotic liver disease . Under. the agreement, GSK will pay $1.2 billion upfront, with potential for. both forms of SLD. Given efimosfermin's direct antifibrotic mechanism of. action and GSK's data-driven insights from ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4588","GSK","LU1829250122.USD","BK4532","ALD","BK4007","BK4134","BK4585","GSK.UK"],"gpt_icon":0},{"id":"2535265647","title":"Press Release: Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2535265647","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535265647?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:00","pubTimestamp":1747134000,"startTime":"0","endTime":"0","summary":"Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutide. Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune's option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","HTGC","LU1878469433.USD","BK4139","BK4135","BK4022","BK4599","R","ALT","ALD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}